The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

The following is a summary of “Reducing time delays and enhancing reperfusion eligibility related to stroke suspicion by the ...

The ambulance would be the latest addition to Florida’s first mobile stroke treatment unit network, which speeds care to ...

Learn the key differences between stroke and migraine symptoms, from onset speed to pain patterns, and know exactly when to ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

After transcatheter patent foramen ovale (PFO) closure, patients with nickel hypersensitivity were more likely to develop ...

UERM Medical Center takes a groundbreaking step in enhancing stroke diagnosis and treatment by launching its new CT-MRI facilities. Attending the event ...

(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Chronic stress can increase young women's risk of stroke, a new study says. Moderate stress increases risk of stroke by 78% ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...